AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8092901
Drug: H2 blocker
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: H2 blocker (continuous infusion of ranitidine at 0.25 mg/kg/hr after a loading dose of 0.5 mg/kg) plus antacids
Trial: 8092901
Drug: Sucralfate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (1 g every 6 hours via nasogastric tube)
Trial: 3287907
Drug: Aspirin 648
RxNorm normalized name: aspirin 648 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 648 mg
Trial: 19029270
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical and surgical treatment
Trial: 15836934
Drug: Stabilisation exercises
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stabilisation exercises (S&G group)
Trial: 15836934
Drug: General exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General exercise only (G group)
Trial: 12207568
Drug: Policosanol 20
RxNorm normalized name: POLICOSANOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Policosanol 20 mg/day
Trial: 12207568
Drug: Policosanol 40
RxNorm normalized name: POLICOSANOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Policosanol 40 mg/day
Trial: 12207568
Drug: Policosanol 20
RxNorm normalized name: POLICOSANOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Policosanol 20 mg/day in hypercholesterolaemic patients
Trial: 12207568
Drug: Policosanol 40
RxNorm normalized name: POLICOSANOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Policosanol 40 mg/day in hypercholesterolaemic patients
Trial: 12207568
Drug: Policosanol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Policosanol (20 and 40 mg/day)
Trial: 11235577
Drug: Zeng Sheng-ping
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zeng Sheng-ping (ZSP), 8 tablets, twice a day for 6 months
Trial: 8670315
Drug: Chimeric anti-TNF
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chimeric anti-TNF alpha antibody cA2 (1 or 10 mg/kg)
Trial: 8670315
Drug: Chimeric anti-TNF
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chimeric anti-TNF alpha antibody cA2
Trial: 1984989
Drug: Albuterol 270
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol 270 micrograms (three puffs) from a metered dose inhaler
Trial: 1984989
Drug: Albuterol 2.5
RxNorm normalized name: levalbuterol 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol 2.5 mg from a saline solution nebulized with an updraft inhaler
Trial: 6135076
Drug: Intravenous (3-amino-1-hydroxypropylidene)-1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (APD)
Trial: 24451697
Drug: Inhaled 1600
RxNorm normalized name: glycerin 1600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled 1600 μg salbutamol
Trial: 22130425
Drug: Sublingual Immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual Immunotherapy followed by Oral Immunotherapy (SLIT/OITB)
Trial: 22130425
Drug: Oral Immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Immunotherapy (OITA)
Trial: 22130425
Drug: Oral Immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Immunotherapy (OITB)
Trial: 17646413
Drug: Voriconazole 200
RxNorm normalized name: voriconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voriconazole 200 mg BID for 3 days, followed by ritonavir 400 mg BID for 10 days, then voriconazole 200 mg BID with ritonavir for 10 days (Study A)
Trial: 17646413
Drug: Voriconazole 200
RxNorm normalized name: voriconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voriconazole 200 mg BID for 3 days, followed by ritonavir 100 mg BID for 10 days, then voriconazole 200 mg BID with ritonavir for 10 days (Study B)
Trial: 17646413
Drug: Voriconazole coadministered
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Voriconazole coadministered with high-dose ritonavir
Trial: 17646413
Drug: Voriconazole coadministered
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Voriconazole coadministered with low-dose ritonavir
Trial: 17646413
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of voriconazole and ritonavir
Trial: 12409716
Drug: Neoadjuvant hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant hormonal therapy with cyproterone acetate (CPA), 300 mg/day for 12 weeks
Trial: 12409716
Drug: Neoadjuvant hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant hormonal therapy with cyproterone acetate (CPA)
Trial: 9793616
Drug: Fast-release test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast-release test preparation (Noricaven novo)
Trial: 7633141
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no specific therapy)
Trial: 3720570
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (10,000 men) received dietary advice, smoking cessation advice, and antihypertensive treatment.
Trial: 29482683
Drug: MTA Angelus
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MTA Angelus plus IRM capsule
Trial: 22615152
Drug: Medial capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medial capsule reefing (Group A)
Trial: 19931756
Drug: Hypertonic lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic lactate saline (HLS) solution
Trial: 15675479
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose mitomycin and epirubicin with caval chemofiltration (CF)
Trial: 15675479
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of mitomycin and epirubicin
Trial: 9248749
Drug: Gentamicin 3
RxNorm normalized name: gentamicin 3 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin 3 mg/kg i.v. bolus and norfloxacin 400 mg twice daily orally from the start
Trial: 9248749
Drug: Cefotaxime 2
RxNorm normalized name: cefotaxime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime 2 g i.v. twice daily for at least two days followed by norfloxacin 400 mg twice daily orally
Trial: 9248749
Drug: Gentamicin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin with early oral therapy
Trial: 4593555
Drug: Acetyl salicylic
RxNorm normalized name: Acetyl salicylic acid specific IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetyl salicylic acid (aspirin) - single daily dose
Trial: 26833624
Drug: Fluticasone nasal
RxNorm normalized name: fluticasone nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone nasal spray for 14 days
Trial: 22886317
Drug: Multidimensional Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidimensional Treatment Foster Care
Trial: 22265994
Drug: Octreotide LAR
RxNorm normalized name: octreotide LAR 20 MG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide LAR 30 mg intramuscular on days 1, 29, and 57, plus daily immediate-release octreotide 600 μg per day and methylprednisolone on days 1 to 6.
Trial: 29567399
Drug: BI 409306
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 409306 25 mg, 50 mg, 100 mg, placebo once daily (OD) for 14 days (Trial 1)
Trial: 29567399
Drug: BI 409306
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 409306 25 mg, 50 mg, placebo OD for 14 days (Trial 2)
Trial: 29567399
Drug: BI 409306
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 409306 25 mg, 50 mg, 100 mg, placebo single doses (SD) (Trial 3)
Trial: 29567399
Drug: BI 409306
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 409306 100 mg SD or placebo for Chinese poor metabolisers (PM) (Trial 3)
Trial: 29567399
Drug: BI 409306
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 409306 100 mg OD for 7 days after a 48-hour washout period (Japanese PM, Trial 3)
Trial: 29567399
Drug: BI 409306
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 409306 (various doses)
Trial: 28778393
Drug: 4.4 g
RxNorm normalized name: ALUMINUM CHLOROHYDRATE 4.4 g in 1 mg BUCCAL EMULSION [Antiperspirant]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.4 g of fish oil
Trial: 12022154
Drug: Tetracycline 500
RxNorm normalized name: oxytetracycline 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline 500 mg for 3 days
Trial: 11910595
Drug: Simvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (10 mg daily) for 8 weeks
Trial: 11910595
Drug: Combined hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined hormone therapy (up to 1.25 mg of conjugated equine estrogens plus 5 mg of medroxyprogesterone acetate daily) for 8 weeks
Trial: 11910595
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of simvastatin and hormone therapy (same dosages as above)
Trial: 6814669
Drug: Naloxone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (2 mg IV)
Trial: 31303007
Drug: Intuitive Movement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intuitive Movement Reembodiment (IMR) program, 10 weekly sessions
Trial: 9149578
Drug: Salmeterol, 100
RxNorm normalized name: Fluticasone-Salmeterol, 100 mcg-50 mcg/inh inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol, 100 micrograms twice daily
Trial: 2439000
Drug: Intramuscular anti-tetanus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular anti-tetanus serum (ATS)
Trial: 25937633
Drug: TM208 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TM208 (50 and 150 mg·kg ‐1 ·d ‐1) for 18 days
Trial: 25937633
Drug: TM208 (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TM208 (10, 15 and 20 μmol/L) in vitro
Trial: 25937633
Drug: Co-treatment with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-treatment with triclosan (inhibitor of sulfonation)
Trial: 16500776
Drug: MoodGYM (cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MoodGYM (cognitive behaviour therapy Internet program)
Trial: 15611398
Drug: Injections of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injections of botulinum toxin type A into the thyroarytenoid muscle(s)
Trial: 11014954
Drug: Weekly oral
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly oral dose of 150 mg fluconazole for 6 months
Trial: 9293648
Drug: 3% hypertonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% hypertonic saline at 7 ml/kg
Trial: 9293648
Drug: Isotonic lactated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic lactated Ringer's solution at 7 mg/kg
Trial: 8299637
Drug: Alteplase 100
RxNorm normalized name: alteplase 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alteplase 100 mg infused over 3 h
Trial: 3571088
Drug: Reinfusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reinfusion of 600 ml of NaCl-glucose-phosphate solution with approximately 50% hematocrit (n = 6)
Trial: 3571088
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (n = 3)
Trial: 31638942
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (referral to a community physiotherapy service)
Trial: 29186803
Drug: Daily Intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Intake Guides (DIG)
Trial: 23513399
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated estrogens and medroxyprogesterone (0.625 mg/d plus medroxyprogesterone 5 mg/d for 10 days)
Trial: 21546627
Drug: CEM‐102 (fusidic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEM‐102 (fusidic acid) administered in single, multiple, and loading doses
Trial: 21546627
Drug: Loading doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading doses of CEM‐102
Trial: 15523294
Drug: Low-dose nesiritide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose nesiritide (0.015 microg/kg/min)
Trial: 15523294
Drug: High-dose nesiritide
RxNorm normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose nesiritide (0.03 microg/kg/min)
Trial: 7506144
Drug: Seaprose S
RxNorm normalized name: S-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seaprose S 60 mg/day
Trial: 3101609
Drug: LNT injection
RxNorm normalized name: NIACINAMIDE 1.5 g in 50 g / TOCOPHEROL 1.5 g in 50 g / 4-BUTYLRESORCINOL 2.5 g in 50 g / ARBUTIN 3.5 g in 50 g TOPICAL CREAM [Lntimate Area]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNT injection following surgical therapy (Ax + Ox)
Trial: 3101609
Drug: LNT injection
RxNorm normalized name: NIACINAMIDE 1.5 g in 50 g / TOCOPHEROL 1.5 g in 50 g / 4-BUTYLRESORCINOL 2.5 g in 50 g / ARBUTIN 3.5 g in 50 g TOPICAL CREAM [Lntimate Area]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNT injection
Trial: 26673586
Drug: Prophylactic nebulised
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic nebulised heparin (50,000 U)
Trial: 22184381
Drug: Docetaxel plus
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel plus vandetanib (100 mg)
Trial: 22184381
Drug: Single-agent vandetanib
RxNorm normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-agent vandetanib (after crossover)
Trial: 19949861
Drug: Internal urethrotomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internal urethrotomy with submucosal injection of triamcinolone (40 mg)
Trial: 17967221
Drug: Strontium ranelate
RxNorm normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Strontium ranelate (SR) treatment for 3 years
Trial: 16002025
Drug: LAAM (100,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAAM (100, 100, 130 mg/MWF) with contingency management (CM)
Trial: 16002025
Drug: LAAM (100,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAAM (100, 100, 130 mg/MWF) without CM
Trial: 16002025
Drug: LAAM (30,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAAM (30, 30, 39 mg/MWF) with CM
Trial: 16002025
Drug: LAAM (30,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAAM (30, 30, 39 mg/MWF) without CM
Trial: 16002025
Drug: LAAM (100,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAAM (100, 100, 130 mg/MWF) with CM
Trial: 11833838
Drug: Combination hydrocodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination hydrocodone 7.5 mg and ibuprofen 200 mg (HC/IB)
Trial: 11833838
Drug: Combination oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination oxycodone 5 mg and acetaminophen 325 mg (OX/AC)
Trial: 10189543
Drug: Metformin combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin combined with standard diet and exercise recommendations
Trial: 2373136
Drug: Terguride 50
RxNorm normalized name: terguride
DrugBank: Terguride (DB13399)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Terguride 50 micrograms i.v. dose
Trial: 2373136
Drug: Terguride 250
RxNorm normalized name: terguride
DrugBank: Terguride (DB13399)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Terguride 250 micrograms oral treatment
Trial: 2373136
Drug: Terguride 500
RxNorm normalized name: terguride
DrugBank: Terguride (DB13399)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Terguride 500 micrograms oral treatment
Trial: 2373136
Drug: Terguride 750
RxNorm normalized name: terguride
DrugBank: Terguride (DB13399)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Terguride 750 micrograms oral treatment
Trial: 2373136
Drug: Terguride (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terguride (all doses)
Trial: 7295072
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of anticholinergics, sulphoglicopeptide and sucralfate
Trial: 9842807
Drug: Information +
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information + modeling + coping-based program (OR tour + videotape + child-life preparation)
Trial: 7510746
Drug: TCR V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TCR V beta 5.2(39-59) and V beta 6.1(39-59) peptides at low doses (100 to 300 micrograms)
Trial: 1101065
Drug: HBIG (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBIG (high concentration of antibodies to surface components of hepatitis B virus, 442 mug per milliliter)
Trial: 1101065
Drug: Control human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control human immune globulin preparation
Trial: 15561379
Drug: Intra-articular analgesics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular analgesics (short acting anaesthetics)
Trial: 11368732
Drug: Salmeterol (42
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol (42 microg twice per day)
Trial: 11368732
Drug: Triamcinolone (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triamcinolone (400 microg twice per day)
Trial: 9164377
Drug: Protocol treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol treatment completion
Trial: 8706197
Drug: Edrophonium 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium 0.25 mg x kg(‐1)
Trial: 8706197
Drug: Edrophonium 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium 0.5 mg x kg(‐1)
Trial: 8706197
Drug: Placebo (0.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.0 mg x kg(‐1) edrophonium)
Trial: 17947502
Drug: Long-duration IH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-duration IH (LDIH) protocol: daily 60-min exposures to normobaric 12% O(2)
Trial: 17947502
Drug: Short-duration IH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-duration IH (SDIH) protocol: twelve 5-min bouts of 12% O(2), separated by 5-min bouts of room air, daily
Trial: 6830410
Drug: Methylphenidate hydrochloride
RxNorm normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate hydrochloride (average, 40 mg/day for up to four years)
Trial: 6830410
Drug: Adjunctive thioridazine
RxNorm normalized name: Thioridazine
DrugBank: Thioridazine (DB00679)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjunctive thioridazine hydrochloride (mean, 87 mg/day)
Trial: 30609411
Drug: Caralluma fimbriata
RxNorm normalized name: CARALLUMA FIMBRIATA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caralluma fimbriata extract (CFE) 500 mg b.d. (n = 49)
Trial: 30609411
Drug: Placebo 500
RxNorm normalized name: placebo 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 500 mg b.d. (n = 48)
Trial: 24123098
Drug: Intensive low-density
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive low-density lipoprotein (LDL)‐lowering therapy with LDL‐apheresis
Trial: 17993364
Drug: diclofenac 50
RxNorm normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diclofenac 50 mg twice daily and placebo manipulative therapy
Trial: 17993364
Drug: spinal manipulative
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: spinal manipulative therapy and placebo drug
Trial: 17993364
Drug: diclofenac 50
RxNorm normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diclofenac 50 mg twice daily and spinal manipulative therapy
Trial: 11942978
Drug: Intravesical BCG
RxNorm normalized name: BCG, live, Tice strain
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical BCG therapy (102 patients)
Trial: 2406439
Drug: Cefoxitin prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin prophylaxis (3 doses of 2g each: initial dose after cord clamping, subsequent doses at 4 and 8 hours)
Trial: 28861803
Drug: Electro-acupuncture (EA)
RxNorm normalized name: ELECTRODE SPRAY,ELECTRO MIST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electro-acupuncture (EA) treatment